Navigation Links
Vical Names Andrew de Guttadauro Vice President, Corporate Development
Date:8/20/2007

SAN DIEGO, Aug. 20 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced the enhancement of its management team with the appointment of Andrew R. de Guttadauro as Vice President, Corporate Development.

Prior to joining Vical, Mr. de Guttadauro was Senior Director of Strategy at Biogen Idec since February 2007, following a two-year assignment overseeing the commercial development of that company's Zevalin, the first radioimmunotherapy product approved for use in the United States. Before joining Biogen Idec, he spent the prior year at MedImmune, where he directed marketing efforts for the FluMist inhaled influenza vaccine. Mr. de Guttadauro served in various marketing positions of increasing responsibility at Amgen Inc. over a six-year period, with direct involvement in the marketing of Enbrel, Kineret, Aranesp, and Epogen products. He spent the first seven years of his career at Tap Pharmaceuticals, where he served in a series of sales and marketing positions, including contributions to the success of Prevacid and Lupron. Mr. de Guttadauro earned a bachelor of science degree in engineering from the United States Military Academy at West Point, followed by a three-year tour of duty as a Captain in the U.S. Army.

Vijay B. Samant, Vical's President and Chief Executive Officer, said, "We are very pleased to welcome Andrew to Vical's management team at this exciting time in the company's development. His proven leadership capabilities, solid project management skills, and breadth of experience in product sales and marketing, add another dimension to our current capabilities. As we advance with our independent product development programs, we look forward to applying Andrew's expertise in p
'/>"/>

SOURCE Vical Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3

Related biology technology :

1. Wisconsin IT association names Gee president, CEO
2. Quintessence Biosciences names new president
3. CDW names VP to handle Berbee merger
4. NimbleGen names CFO with capital-raising past
5. Cisco names Berbee a top partner of 2005
6. Cisco names Inacom most innovative partner
7. UW-Madison medical school names new dean
8. GE Healthcare names new CEO
9. Bruker AXS names new leadership
10. Sonic Foundry names new senior vice president
11. MyWeather names new president, marketing officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Plant disease specialists from around the ... Annual Meeting of The American Phytopathological Society. Details ... now at APSnet.org/meet . , The Preliminary Daily ... be held August 1-5, 2015 in Pasadena, California, U.S.A. ... Workshops, and committee meetings, all carefully balanced to deliver ...
(Date:3/5/2015)... Bi-Biomics today announced a discovery made ... The improvement in histological quality provided the detail ... all daughter cells. , After processing with Ultralight ... at 1000-1600x using light microscopy. Phylogenetic and ... daughter cells displayed predominant binary features --- one ...
(Date:3/5/2015)... TORONTO , March 5, 2015 /PRNewswire/ - Aptose ... developing new therapeutics and molecular diagnostics that target the ... G. Rice , Ph.D., Chairman, President and Chief Executive ... Conference on Tuesday, March 10 th at 9:30 ... Laguna Niguel, CA. Dr. Rice will provide ...
(Date:3/5/2015)... DUBLIN , Mar. 05, 2015 Research and ... addition of the "Mature Biotech Outlook 2015: New ... to their offering. All biotech companies ... Celgene (CELG), in past year, have given a positive ... These companies have been able to select therapy/niche indication ...
Breaking Biology Technology:American Phytopathological Society Announces Annual Meeting Daily Schedule 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3
... Elbit Medical,Imaging Ltd. (Nasdaq: EMITF ) ("EMI") today ... has entered into definitive agreements,with one of the leading ... of a large scale mixed-use project located in,Bangalore, Karnataka, ... an Indian company to be,held in equal parts by ...
... PRINCETON, N.J., Oct. 22 Pharmacopeia,(Nasdaq: PCOP ), ... molecule therapeutics, today announced that Dr. Leslie J. Browne,President ... the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare,Conference. ... 2007, at the New,York Palace Hotel in New York ...
... Boston,Scientific Corporation (NYSE: BSX ) today ... from its TAXUS ARRIVE 1 and 2 registries, ... Paclitaxel-Eluting,Coronary Stent System in "real-world" practice. The pooled ... and repeat,revascularization through two years in complex patients ...
Cached Biology Technology:Elbit Medical Imaging Ltd. Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore, India 2Elbit Medical Imaging Ltd. Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore, India 3Elbit Medical Imaging Ltd. Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore, India 4Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 3Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 4ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 2ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 3ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 4
(Date:2/24/2015)... , Feb. 24, 2015 Research and Markets ... addition of the "Global 2D Gesture Recognition ... The analysts forecast the Global 2D ... of 32.12% over the period 2014-2019 ... non-traditional sectors is one of the major trends ...
(Date:2/13/2015)... , Feb. 13, 2015 ACT Genomics ... that aims to transform cancer genomic information into ... the company has raised US$ 8 million in the ... in Taipei, Taiwan , ACT ... ACTOnco™. With the aim to implement next generation ...
(Date:2/10/2015)... 10, 2015  Alere Inc. (NYSE: ALR), a ... results for the quarter ended December 31, 2014. ... President of Alere said, "We made substantial progress ... the global leader in rapid diagnostics and delivering ... Health divestiture in early January enabled us to ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34
... long looked to the future when a damaged heart could ... A study published in the February issue of Circulation ... that heart stem cells from children with congenital heart disease ... Sunjay Kaushal, MD, PhD, surgeon ...
... the field of cardiac therapeutics have long looked to the ... by using one,s own heart cells. A study published in ... of the American Heart Association, shows that heart stem cells ... the damaged heart in an animal model. ...
... scientist is digging deep to solidify information about potential ... Tungsten is a naturally occurring metallic element that in ... incandescent lightbulb filaments and X-ray tubes. In an ... replacing lead in fishing weights and in ammunition for ...
Cached Biology News:Stem cells show promise in repairing a child's heart 2Using a child's own stem cells to repair their heart looks promising 2National study explores the reaction and transport of tungsten in drinking water 2
Coating : Poly-D-Lysine ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vol working : 2.5-3.0 ml ...
...
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
... primers are designed for sequencing inserts cloned ... T7, or T3 RNA polymerase promoters, or ... supplied at a concentration of 0.1 µg/µl ... in DNA sequencing reactions using SequiTherm™ EXCEL™ ...
Biology Products: